Law360, New York (September 10, 2008, 12:00 AM EDT) -- A federal judge on Tuesday refused to dismiss a proposed class action against Mylan Laboratories Inc. that alleges the company's arthritis treatment piroxicam, a generic version of Pfizer Inc.'s Feldene, puts users at increased risk for a disease that causes severe rashes and blisters.
Judge Reginald C. Lindsay of the U.S. District Court for the District of Massachusetts denied Mylan's motion to dismiss the suit "in light of the filing of an amended complaint" on Aug. 25.
The suit, first filed in February, alleges that Mylan's...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.